160 related articles for article (PubMed ID: 18665327)
1. Bowel perforation in non-small cell lung cancer after bevacizumab therapy.
Schellhaas E; Loddenkemper C; Schmittel A; Buhr HJ; Pohlen U
Invest New Drugs; 2009 Apr; 27(2):184-7. PubMed ID: 18665327
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
Sandler A; Gray R; Perry MC; Brahmer J; Schiller JH; Dowlati A; Lilenbaum R; Johnson DH
N Engl J Med; 2006 Dec; 355(24):2542-50. PubMed ID: 17167137
[TBL] [Abstract][Full Text] [Related]
3. [Ischemic anastomotic bowel perforation during treatment with bevacizumab 10 months after surgery].
Abbrederis K; Kremer M; Schuhmacher C
Chirurg; 2008 Apr; 79(4):351-5. PubMed ID: 17453167
[TBL] [Abstract][Full Text] [Related]
4. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab: optimal dose, schedule, and duration of therapy.
Gandara DR; Sangha R; Davies AM
Clin Lung Cancer; 2007 Nov; 8(9):522-3. PubMed ID: 18186957
[No Abstract] [Full Text] [Related]
6. Angiogenesis inhibition in the treatment of lung cancer.
Vokes E; Herbst R; Sandler A
Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
[TBL] [Abstract][Full Text] [Related]
7. Hepatic portal venous gas in a patient with metastatic non-small cell lung cancer on bevacizumab therapy: a case report and review of the literature.
Ortega J; Hayes JM; Antonia S
Cancer Chemother Pharmacol; 2009 Dec; 65(1):187-90. PubMed ID: 19697030
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab, paclitaxel and carboplatin for advanced ovarian cancer: low risk of gastrointestinal and cardiovascular toxicity.
Abaid LN; Lopez KL; Micha JP; Rettenmaier MA; Brown JV; Goldstein BH
Eur J Gynaecol Oncol; 2010; 31(3):308-11. PubMed ID: 21077475
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab in the treatment of ovarian cancer.
Han ES; Monk BJ
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab-based therapy and complication risk after colonic stent placement: is it time for a warning?
Fuccio L; Cennamo V
Gastrointest Endosc; 2010 Dec; 72(6):1330; author reply 1330-2. PubMed ID: 21111886
[No Abstract] [Full Text] [Related]
12. A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016).
Miura S; Maemondo M; Iwashima A; Harada T; Sugawara S; Kobayashi K; Inoue A; Nakagawa T; Takiguchi Y; Watanabe H; Ishida T; Terada M; Kagamu H; Gemma A; Yoshizawa H
Invest New Drugs; 2017 Apr; 35(2):227-234. PubMed ID: 28150074
[TBL] [Abstract][Full Text] [Related]
13. Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab.
Gray J; Murren J; Sharma A; Kelley S; Detterbeck F; Bepler G
J Thorac Oncol; 2007 Jun; 2(6):571-3. PubMed ID: 17545855
[TBL] [Abstract][Full Text] [Related]
14. Endoscopic management of colonic perforation owing to angiogenesis inhibitors.
Ezzedine S; Bege T; Berdah S; Vitton V; Grimaud JC; Barthet M
Surg Laparosc Endosc Percutan Tech; 2010 Dec; 20(6):e230-2. PubMed ID: 21150409
[TBL] [Abstract][Full Text] [Related]
15. Improved survival with addition of bevacizumab to paclitaxel and carboplatin in elderly patients with non-small-cell lung cancer.
Atkins CD
J Clin Oncol; 2008 Apr; 26(12):2063-4; author reply 2064-5. PubMed ID: 18421066
[No Abstract] [Full Text] [Related]
16. Bevacizumab, Carboplatin and Paclitaxel Combination Treatment in Advanced Stage Ovarian Cancer: The First Experience in Thammasat University Hospital, Thailand: A Case Report.
Suwannarurk K; Thaweekul Y; Mairaing K; Poomtavorn Y; Tangtiang K; Piyawang W; Bhamarapravatana K
J Med Assoc Thai; 2015 Apr; 98 Suppl 3():S121-5. PubMed ID: 26387399
[TBL] [Abstract][Full Text] [Related]
17. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer.
Hainsworth JD; Fang L; Huang JE; Karlin D; Russell K; Faoro L; Azzoli C
J Thorac Oncol; 2011 Jan; 6(1):109-14. PubMed ID: 21107290
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab for non-small-cell lung cancer.
Garassino MC; Hollander L; Torri V
N Engl J Med; 2007 Mar; 356(13):1373; author reply 1374-5. PubMed ID: 17392310
[No Abstract] [Full Text] [Related]
19. Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers.
Abu-Hejleh T; Mezhir JJ; Goodheart MJ; Halfdanarson TR
Curr Oncol Rep; 2012 Aug; 14(4):277-84. PubMed ID: 22532266
[TBL] [Abstract][Full Text] [Related]
20. Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer.
Twelves C; Chmielowska E; Havel L; Popat S; Swieboda-Sadlej A; Sawrycki P; Bycott P; Ingrosso A; Kim S; Williams JA; Chen C; Olszanski AJ; de Besi P; Schiller JH
Ann Oncol; 2014 Jan; 25(1):132-8. PubMed ID: 24356624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
